News | July 28, 2021
Bharat Immunologicals and Biologicals Corporation Q1FY22 net profit at Rs. 1.92 Cr
The company reported total income Rs.18.57 crores during the period ended June 30, 2020.
The company reported total income Rs.18.57 crores during the period ended June 30, 2020.
The company posted net profit of Rs.321 crores for the period ended June 30, 2020.
The company posted net profit of Rs.594.6 crores for the period ended June 30, 2020.
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
The company posted net loss of Rs.56.69 crores for the period ended June 30, 2020.
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
The US business faced price erosion due to increased competition.
The company is confident of commencing production at both Mahad and Chiplun units soon
It posted net (loss) of Rs.(34.13) crores for the period ended June 30, 2020.
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
Subscribe To Our Newsletter & Stay Updated
